Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine in early stage Huntington Disease
NCT04556656Phase 3Completed
- Sponsor
- Prilenia Therapeutics
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Pridopidine with Placebo (2 arms). Primary endpoint: Unified Huntington Disease Rating Scale-Total Functional Capacity at 65 weeks. Started Oct 2020; status: completed.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT04556656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556656.